Bruce D. Broussard

October 17, 2026

MRSH Q3 Beat on Consulting Growth, Resilience Coalition Launched. Marsh McLennan's third-quarter earnings beat estimates, propelled by growth in consulting and AI-driven initiatives despite higher costs. The company also launched a Resilience Coalition to address rising global business risks. Meanwhile, analysts weigh margin and growth risks, with some trimming fair value estimates due to a challenging operating environment.

October 17, 2026

Takeda Launches Narcolepsy Drug in Asia, Presents PID Study Data. Takeda has launched its new narcolepsy treatment, ORZEYFUL, in Japan and China, marking the first availability of this orexin agonist for patients with narcolepsy type 1. The company also presented Phase 2/3 clinical data for its investigational drug TAK-881 for primary immunodeficiency disease at a recent medical conference. These pipeline advancements represent key milestones in Takeda's therapeutic portfolio expansion.

October 17, 2026

HPQ earnings beat followed by stock decline. HP reported earnings that exceeded analysts' expectations, marking a positive surprise for the quarter. Despite the beat, the shares fell more than the broader market, drawing fresh attention to the stock's recent weakness. The price is now near a long‑standing support level around $24.05, a point that has been tested many times.

October 17, 2026

Humana to drop 37 PPOs for 2027 Medicare Advantage plans. Humana announced it will discontinue 37 Preferred Provider Organization (PPO) plans for the 2027 Medicare Advantage enrollment period. The company noted that affected members may qualify for a Medigap open enrollment window without health questions. This structural change impacts the company's product lineup and member retention strategies for the upcoming year.